<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041172</identifier>
<setSpec>0378-4835</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Use of transdermic fentanyl by a department of home medical care of terminal oncologic patients</dc:title>
<dc:description xml:lang="en">&#149; Purpose: An observational and retrospective study was performed in order to evaluate the activity andtoxicity of transdermal fentanyl in patients with advanced cancer.&#149; Material and methods: 112 patients treated by a home palliative care unit were studied. Thecharacteristics of patients, analgesic treatments, and opioid rotation were analysed from the beginning offentanyl administration to the death.&#149; Results: The mean age of the patients (p) was 71.5 years (range, 29-88). The indication for opioidadministration was pain in 102 and dyspnea in 10 patients. The type of pain was visceral in 56 p (55%), bonyin 25 p (25%), neuropatic in 13 p (12.8%), muscular in 5 p (5%), and others in 3 p (2.1%). The baseline meanvalue of the pain analogical visual scale (AVS) was 5.9. The analgesics administered before fentanyl was givenwere tramadol (32.2%), NSAIDs (31%), morphine (31%) and codeine (5.6%). The median initial dose offentanyl was 50 µg (range, 25-300). The final mean dose at the time of death was 75 µg (25-400). The finalmean AVS was 3.3. The median treatment duration was 44 days (range, 1 to 372). It caused G2-3 nausea in 35p (31%), somnolence in 13 p, and agitation in 5 p; 81 patients received laxatives. Opioid rotation withmorphine was necessary in 10 p because of toxicity, and in 6 p because uncontrolled pain.&#149; Conclusions: Transdermal fentanyl is a well tolerated analgesic in patients with advanced cancer,providing a good analgesia in up to 91% of the patients previously treated with opioids, as well as of thepatients proceeding directly from the first or second step of the WHO ladder</dc:description>
<dc:creator>Tres Sánchez, A</dc:creator>
<dc:creator>Escudero Emperador, P</dc:creator>
<dc:creator>Andrés Conejero, R</dc:creator>
<dc:creator>Pérez-Caballero, M. C</dc:creator>
<dc:creator>Aguirre Ortega, E</dc:creator>
<dc:creator>Lambea Sorrosal, J</dc:creator>
<dc:creator>Mayordomo Cámara, J. I</dc:creator>
<dc:creator>Isla Casado, D</dc:creator>
<dc:creator>Lastra del Prado, R</dc:creator>
<dc:creator>Ortega Izquierdo, M. E</dc:creator>
<dc:creator>Sáenz Cusi, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">&#149; Propósito: Se ha realizado un estudio observacional y retrospectivo para evaluar el modo de utilizacióny los efectos secundarios de fentanilo transdérmico (FTTS) en pacientes oncológicos en situación terminal.&#149; Material y métodos: Se han evaluado estadísticamente pacientes incluidos en un programa de AtenciónDomiciliaria que recibieron tratamiento con FTTS.&#149; Resultados: 112 pacientes (p) recibieron tratamiento con FTTS. Mediana de edad de 71.5 años (29-88).102p presentaban dolor y 10 disnea. Tipo de dolor: visceral 55% p, óseo 25% p, neuropático 12.5%, muscular5% p y otro 2.5% p. EVA inicial: media 5.9. La analgesia previa a la utilización de fentanilo fue: 31% p AINES,32.2% p tramadol, 5.6% p codeína y 31% p morfina. La dosis mediana inicial de fentanilo fue 50mgr/hora(25-300). La dosis mediana final fue 75 mgr/hora (25-400). EVA final media: 3,3. La mediana de la duracióndel tratamiento fue de 44 días (1-372). 35 p (31%) presentaron náuseas G2-3, somnolencia 5 p, agitacióny/o delirio 13 p. 81 p (72%) precisaron laxantes. En 10 p fue necesario rotar a otro opioide: 4 p por toxicidad y6 p por mal control del dolor.&#149; Conclusiones: El FTTS es un analgésico bien tolerado en pacientes terminales y proporciona una analgesiaadecuada (91%), a un bajo coste en cuanto a yatrogenia intolerable (4%), tanto con paso previo conopioides como directamente desde primer escalón analgésico OMS</dc:description>
<dc:source>Oncologia;28(10): 477-482, oct. 2005. tab</dc:source>
<dc:identifier>ibc-041172</dc:identifier>
<dc:title xml:lang="es">El uso de fentanilo transdérmico por una unidad de atención domiciliaria en pacientes oncológicos en el final de la vida</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d712^s22045</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d10353^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6858^s22045</dc:subject>
<dc:subject>^d28037^s22000</dc:subject>
<dc:subject>^d10334^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
